Want to join the conversation?
$BMY said the company's R&D expenses increased to $1.1Bil in 2Q16, primarily due to grants. The company said it now expects R&D spend to increase in the mid teens range, driven by investments in Opdivo and other immuno-oncology programs. This also relates to the increased spending related to business development transactions completed in FY16.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.
Impressed with $AMZN’s latest grocery ambitions. The new Amazon Go convenience store, is an absolute game changer.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$